Predicting and preventing the future: actively managing multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Neuroscience

Background:

• Relapsing-remitting multiple sclerosis (MS) presents a variable clinical course.
• Early inflammatory activity in MS significantly contributes to later neurodegenerative changes.
• A substantial proportion of patients exhibit suboptimal responses to conventional first-line therapies.

Purpose of the Study:

• To highlight the importance of early disease activity assessment in relapsing-remitting MS.
• To emphasize the role of advanced therapies in managing MS inflammation.
• To advocate for treatment optimization strategies to prevent secondary progressive MS.

Main Methods:

• Review of clinical, demographic, and MRI features for disease activity assessment.
• Analysis of treatment responses to first-line and second-line therapies.
• Development of recommendations for treatment optimization based on clinical response.

Main Results:

• Demographic, clinical, and MRI data aid in predicting MS disease activity and outcomes.
• First-line therapies partially control relapses, with one-third of patients showing suboptimal response.
• Highly active second-line therapies demonstrate significant inflammation suppression.

Conclusions:

• Effective management of early relapsing-remitting MS requires active intervention.
• Treatment optimization based on initial response is key to preventing disability progression.
• Early and aggressive management can mitigate the transition to secondary progressive MS.